Emmanuel J Favaloro/LinkedIn
Aug 21, 2025, 14:55
Emmanuel Favaloro on DOACs Versus Warfarin in the COVID19 Era
“Did the COVID19 pandemic push the use of DOACs to the lead in the ‘anticoagulant race’, and ahead of warfarin?
Well, yes and no.
Depends on where you live. Check out this Commentary in Seminars in Thrombosis and Hemostasis.
Just released online.
Enjoy!”
Stay informed with Hemostasis Today.
-
Jul 30, 2026, 18:36Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
-
Jul 30, 2026, 18:11Tobias Tritschler: Evaluating Timing, Translation and Preparedness in COVID-19 Anticoagulation Management
-
Jul 30, 2026, 16:05Peter Zdziarski: Today is Chronic Disease Awareness Day
-
Jul 30, 2026, 15:50Ahmad Gharehbaghian: New Blood Transfusion Centers Open in Iran
-
Jul 30, 2026, 15:32Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal
-
Jul 30, 2026, 15:162025 Platelet Transfusion Thresholds: When to Transfuse and When Not to Transfuse – Chokri Ben Lamine
-
Jul 30, 2026, 14:34Flora Peyvandi: Genetics of Early-Onset Coronary Artery Disease in Iranians
-
Jul 30, 2026, 14:22Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
-
Jul 30, 2026, 14:09Hilal Ahmad: New Guidelines for Pediatric Ischemic Stroke Management